Tag Archives: world
#437687 Video Friday: Bittle Is a Palm-Sized ...
Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):
ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online]
IROS 2020 – October 25-29, 2020 – [Online]
CYBATHLON 2020 – November 13-14, 2020 – [Online]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today's videos.
Rongzhong Li, who is responsible for the adorable robotic cat Nybble, has an updated and even more adorable quadruped that's more robust and agile but only costs around US $200 in kit form on Kickstarter.
Looks like the early bird options are sold out, but a full kit is a $225 pledge, for delivery in December.
[ Kickstarter ]
Thanks Rz!
I still maintain that Stickybot was one of the most elegantly designed robots ever.
[ Stanford ]
With the unpredictable health crisis of COVID-19 continuing to place high demands on hospitals, PAL Robotics have successfully completed testing of their delivery robots in Barcelona hospitals this summer. The TIAGo Delivery and TIAGo Conveyor robots were deployed in Hospital Municipal of Badalona and Hospital Clínic Barcelona following a winning proposal submitted to the European DIH-Hero project. Accerion sensors were integrated onto the TIAGo Delivery Robot and TIAGo Conveyor Robot for use in this project.
[ PAL Robotics ]
Energy Robotics, a leading developer of software solutions for mobile robots used in industrial applications, announced that its remote sensing and inspection solution for Boston Dynamics’s agile mobile robot Spot was successfully deployed at Merck’s thermal exhaust treatment plant at its headquarters in Darmstadt, Germany. Energy Robotics equipped Spot with sensor technology and remote supervision functions to support the inspection mission.
Combining Boston Dynamics’ intuitive controls, robotic intelligence and open interface with Energy Robotics’ control and autonomy software, user interface and encrypted cloud connection, Spot can be taught to autonomously perform a specific inspection round while being supervised remotely from anywhere with internet connectivity. Multiple cameras and industrial sensors enable the robot to find its way around while recording and transmitting information about the facility’s onsite equipment operations.
Spot reads the displays of gauges in its immediate vicinity and can also zoom in on distant objects using an externally-mounted optical zoom lens. In the thermal exhaust treatment facility, for instance, it monitors cooling water levels and notes whether condensation water has accumulated. Outside the facility, Spot monitors pipe bridges for anomalies.
Among the robot’s many abilities, it can detect defects of wires or the temperature of pump components using thermal imaging. The robot was put through its paces on a comprehensive course that tested its ability to handle special challenges such as climbing stairs, scaling embankments and walking over grating.
[ Energy Robotics ]
Thanks Stefan!
Boston Dynamics really should give Dr. Guero an Atlas just to see what he can do with it.
[ DrGuero ]
World's First Socially Distanced Birthday Party: Located in London, the robotic arm was piloted in real time to light the candles on the cake by the founder of Extend Robotics, Chang Liu, who was sat 50 miles away in Reading. Other team members in Manchester and Reading were also able to join in the celebration as the robot was used to accurately light the candles on the birthday cake.
[ Extend Robotics ]
The Robocon in-person competition was canceled this year, but check out Tokyo University's robots in action:
[ Robocon ]
Sphero has managed to pack an entire Sphero into a much smaller sphere.
[ Sphero ]
Squishy Robotics, a small business funded by the National Science Foundation (NSF), is developing mobile sensor robots for use in disaster rescue, remote monitoring, and space exploration. The shape-shifting, mobile, senor robots from UC-Berkeley spin-off Squishy Robotics can be dropped from airplanes or drones and can provide first responders with ground-based situational awareness during fires, hazardous materials (HazMat) release, and natural and man-made disasters.
[ Squishy Robotics ]
Meet Jasper, the small girl with big dreams to FLY. Created by UTS Animal Logic Academy in partnership with the Royal Australian Air Force to encourage girls to soar above the clouds. Jasper was created using a hybrid of traditional animation techniques and technology such as robotics and 3D printing. A KUKA QUANTEC robot is used during the film making to help the Australian Royal Airforce tell their story in a unique way. UTS adapted their High Accurate robot to film consistent paths, creating a video with physical sets and digital characters.
[ AU AF ]
Impressive what the Ghost Robotics V60 can do without any vision sensors on it.
[ Ghost Robotics ]
Is your job moving tiny amounts of liquid around? Would you rather be doing something else? ABB’s YuMi got you.
[ Yumi ]
For his PhD work at the Media Lab, Biomechatronics researcher Roman Stolyarov developed a terrain-adaptive control system for robotic leg prostheses. as a way to help people with amputations feel as able-bodied and mobile as possible, by allowing them to walk seamlessly regardless of the ground terrain.
[ MIT ]
This robot collects data on each cow when she enters to be milked. Milk samples and 3D photos can be taken to monitor the cow’s health status. The Ontario Dairy Research Centre in Elora, Ontario, is leading dairy innovation through education and collaboration. It is a state-of-the-art 175,000 square foot facility for discovery, learning and outreach. This centre is a partnership between the Agricultural Research Institute of Ontario, OMAFRA, the University of Guelph and the Ontario dairy industry.
[ University of Guleph ]
Australia has one of these now, should the rest of us panic?
[ Boeing ]
Daimler and Torc are developing Level 4 automated trucks for the real world. Here is a glimpse into our closed-course testing, routes on public highways in Virginia, and self-driving capabilities development. Our year of collaborating on the future of transportation culminated in the announcement of our new truck testing center in New Mexico.
[ Torc Robotics ] Continue reading
Posted in Human Robots
#437673 Can AI and Automation Deliver a COVID-19 ...
Illustration: Marysia Machulska
Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.
“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.
In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.
Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.
There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”
That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.
“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”
There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.
Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, antivirals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.
The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.
But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.
Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.
And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.
While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”
Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.
Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.
Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.
And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.
To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”
Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.
1/5
STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot
2/5
STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.
3/5
STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.
4/5
STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.
5/5
STEP 5: The most promising compounds are tested against live virus samples.
Previous
Next
Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.
For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.
The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.
Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.
That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.
First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.
Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.
Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.
Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s AI-generated molecules in virtual reality.
Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.
Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.
Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.
Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.
The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.
Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.
Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.
While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.
In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.
“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.
While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.
“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”
This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading
Posted in Human Robots
#437667 17 Teams to Take Part in DARPA’s ...
Among all of the other in-person events that have been totally wrecked by COVID-19 is the Cave Circuit of the DARPA Subterranean Challenge. DARPA has already hosted the in-person events for the Tunnel and Urban SubT circuits (see our previous coverage here), and the plan had always been for a trio of events representing three uniquely different underground environments in advance of the SubT Finals, which will somehow combine everything into one bonkers course.
While the SubT Urban Circuit event snuck in just under the lockdown wire in late February, DARPA made the difficult (but prudent) decision to cancel the in-person Cave Circuit event. What this means is that there will be no Systems Track Cave competition, which is a serious disappointment—we were very much looking forward to watching teams of robots navigating through an entirely unpredictable natural environment with a lot of verticality. Fortunately, DARPA is still running a Virtual Cave Circuit, and 17 teams will be taking part in this competition featuring a simulated cave environment that’s as dynamic and detailed as DARPA can make it.
From DARPA’s press releases:
DARPA’s Subterranean (SubT) Challenge will host its Cave Circuit Virtual Competition, which focuses on innovative solutions to map, navigate, and search complex, simulated cave environments November 17. Qualified teams have until Oct. 15 to develop and submit software-based solutions for the Cave Circuit via the SubT Virtual Portal, where their technologies will face unknown cave environments in the cloud-based SubT Simulator. Until then, teams can refine their roster of selected virtual robot models, choose sensor payloads, and continue to test autonomy approaches to maximize their score.
The Cave Circuit also introduces new simulation capabilities, including digital twins of Systems Competition robots to choose from, marsupial-style platforms combining air and ground robots, and breadcrumb nodes that can be dropped by robots to serve as communications relays. Each robot configuration has an associated cost, measured in SubT Credits – an in-simulation currency – based on performance characteristics such as speed, mobility, sensing, and battery life.
Each team’s simulated robots must navigate realistic caves, with features including natural terrain and dynamic rock falls, while they search for and locate various artifacts on the course within five meters of accuracy to score points during a 60-minute timed run. A correct report is worth one point. Each course contains 20 artifacts, which means each team has the potential for a maximum score of 20 points. Teams can leverage numerous practice worlds and even build their own worlds using the cave tiles found in the SubT Tech Repo to perfect their approach before they submit one official solution for scoring. The DARPA team will then evaluate the solution on a set of hidden competition scenarios.
Of the 17 qualified teams (you can see all of them here), there are a handful that we’ll quickly point out. Team BARCS, from Michigan Tech, was the winner of the SubT Virtual Urban Circuit, meaning that they may be the team to beat on Cave as well, although the course is likely to be unique enough that things will get interesting. Some Systems Track teams to watch include Coordinated Robotics, CTU-CRAS-NORLAB, MARBLE, NUS SEDS, and Robotika, and there are also a handful of brand new teams as well.
Now, just because there’s no dedicated Cave Circuit for the Systems Track teams, it doesn’t mean that there won’t be a Cave component (perhaps even a significant one) in the final event, which as far as we know is still scheduled to happen in fall of next year. We’ve heard that many of the Systems Track teams have been testing out their robots in caves anyway, and as the virtual event gets closer, we’ll be doing a sort of Virtual Systems Track series that highlights how different teams are doing mock Cave Circuits in caves they’ve found for themselves.
For more, we checked in with DARPA SubT program manager Dr. Timothy H. Chung.
IEEE Spectrum: Was it a difficult decision to cancel the Systems Track for Cave?
Tim Chung: The decision to go virtual only was heart wrenching, because I think DARPA’s role is to offer up opportunities that may be unimaginable for some of our competitors, like opening up a cave-type site for this competition. We crawled and climbed through a number of these sites, and I share the sense of disappointment that both our team and the competitors have that we won’t be able to share all the advances that have been made since the Urban Circuit. But what we’ve been able to do is pour a lot of our energy and the insights that we got from crawling around in those caves into what’s going to be a really great opportunity on the Virtual Competition side. And whether it’s a global pandemic, or just lack of access to physical sites like caves, virtual environments are an opportunity that we want to develop.
“The simulator offers us a chance to look at where things could be … it really allows for us to find where some of those limits are in the technology based only on our imagination.”
—Timothy H. Chung, DARPA
What kind of new features will be included in the Virtual Cave Circuit for this competition?
I’m really excited about these particular features because we’re seeing an opportunity for increased synergy between the physical and the virtual. The first I’d say is that we scanned some of the Systems Track robots using photogrammetry and combined that with some additional models that we got from the systems competitors themselves to turn their systems robots into virtual models. We often talk about the sim to real transfer and how successful we can get a simulation to transfer over to the physical world, but now we’ve taken something from the physical world and made it virtual. We’ve validated the controllers as well as the kinematics of the robots, we’ve iterated with the systems competitors themselves, and now we have these 13 robots (air and ground) in the SubT Tech Repo that now all virtual competitors can take advantage of.
We also have additional robot capability. Those comms bread crumbs are common among many of the competitors, so we’ve adopted that in the virtual world, and now you have comms relay nodes that are baked in to the SubT Simulator—you can have either six or twelve comms nodes that you can drop from a variety of our ground robot platforms. We have the marsupial deployment capability now, so now we have parent ground robots that can be mixed and matched with different child drones to become marsupial pairs.
And this is something I’ve been planning for for a while: we now have the ability to trigger things like rock falls. They still don’t quite look like Indiana Jones with the boulder coming down the corridor, but this comes really close. In addition to it just being an interesting and realistic consideration, we get to really dynamically test and stress the robots’ ability to navigate and recognize that something has changed in the environment and respond to it.
Image: DARPA
DARPA is still running a Virtual Cave Circuit, and 17 teams will be taking part in this competition featuring a simulated cave environment.
No simulation is perfect, so can you talk to us about what kinds of things aren’t being simulated right now? Where does the simulator not match up to reality?
I think that question is foundational to any conversation about simulation. I’ll give you a couple of examples:
We have the ability to represent wholesale damage to a robot, but it’s not at the actuator or component level. So there’s not a reliability model, although I think that would be really interesting to incorporate so that you could do assessments on things like mean time to failure. But if a robot falls off a ledge, it can be disabled by virtue of being too damaged to continue.
With communications, and this is one that’s near and dear not only to my heart but also to all of those that have lived through developing communication systems and robotic systems, we’ve gone through and conducted RF surveys of underground environments to get a better handle on what propagation effects are. There’s a lot of research that has gone into this, and trying to carry through some of that realism, we do have path loss models for RF communications baked into the SubT Simulator. For example, when you drop a bread crumb node, it’s using a path loss model so that it can represent the degradation of signal as you go farther into a cave. Now, we’re not modeling it at the Maxwell equations level, which I think would be awesome, but we’re not quite there yet.
We do have things like battery depletion, sensor degradation to the extent that simulators can degrade sensor inputs, and things like that. It’s just amazing how close we can get in some places, and how far away we still are in others, and I think showing where the limits are of how far you can get simulation is all part and parcel of why SubT Challenge wants to have both System and Virtual tracks. Simulation can be an accelerant, but it’s not going to be the panacea for development and innovation, and I think all the competitors are cognizant those limitations.
One of the most amazing things about the SubT Virtual Track is that all of the robots operate fully autonomously, without the human(s) in the loop that the System Track teams have when they compete. Why make the Virtual Track even more challenging in that way?
I think it’s one of the defining, delineating attributes of the Virtual Track. Our continued vision for the simulation side is that the simulator offers us a chance to look at where things could be, and allows for us to explore things like larger scales, or increased complexity, or types of environments that we can’t physically gain access to—it really allows for us to find where some of those limits are in the technology based only on our imagination, and this is one of the intrinsic values of simulation.
But I think finding a way to incorporate human input, or more generally human factors like teleoperation interfaces and the in-situ stress that you might not be able to recreate in the context of a virtual competition provided a good reason for us to delineate the two competitions, with the Virtual Competition really being about the role of fully autonomous or self-sufficient systems going off and doing their solution without human guidance, while also acknowledging that the real world has conditions that would not necessarily be represented by a fully simulated version. Having said that, I think cognitive engineering still has an incredibly important role to play in human robot interaction.
What do we have to look forward to during the Virtual Competition Showcase?
We have a number of additional features and capabilities that we’ve baked into the simulator that will allow for us to derive some additional insights into our competition runs. Those insights might involve things like the performance of one or more robots in a given scenario, or the impact of the environment on different types of robots, and what I can tease is that this will be an opportunity for us to showcase both the technology and also the excitement of the robots competing in the virtual environment. I’m trying not to give too many spoilers, but we’ll have an opportunity to really get into the details.
Check back as we get closer to the 17 November event for more on the DARPA SubT Challenge. Continue reading
Posted in Human Robots